IL243311B - Novel antibody frameworks - Google Patents
Novel antibody frameworksInfo
- Publication number
- IL243311B IL243311B IL243311A IL24331115A IL243311B IL 243311 B IL243311 B IL 243311B IL 243311 A IL243311 A IL 243311A IL 24331115 A IL24331115 A IL 24331115A IL 243311 B IL243311 B IL 243311B
- Authority
- IL
- Israel
- Prior art keywords
- human
- antibody
- nucleic acid
- seq
- domain
- Prior art date
Links
- 241000282414 Homo sapiens Species 0.000 claims description 138
- 150000007523 nucleic acids Chemical group 0.000 claims description 72
- 210000004602 germ cell Anatomy 0.000 claims description 70
- 239000012634 fragment Substances 0.000 claims description 41
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 34
- 239000013598 vector Substances 0.000 claims description 27
- 230000027455 binding Effects 0.000 claims description 25
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 23
- 102000036639 antigens Human genes 0.000 claims description 23
- 108091007433 antigens Proteins 0.000 claims description 23
- 210000004027 cell Anatomy 0.000 claims description 23
- 239000000427 antigen Substances 0.000 claims description 22
- 125000000539 amino acid group Chemical group 0.000 claims description 11
- 241000283984 Rodentia Species 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 238000010367 cloning Methods 0.000 claims description 8
- 238000005516 engineering process Methods 0.000 claims description 7
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 5
- 230000004927 fusion Effects 0.000 claims description 4
- 238000002965 ELISA Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 2
- 238000004113 cell culture Methods 0.000 claims description 2
- 239000012228 culture supernatant Substances 0.000 claims description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims description 2
- 210000001806 memory b lymphocyte Anatomy 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 1
- 230000035772 mutation Effects 0.000 description 42
- 108091035707 Consensus sequence Proteins 0.000 description 26
- 108090000623 proteins and genes Proteins 0.000 description 25
- 102000004169 proteins and genes Human genes 0.000 description 23
- 235000018102 proteins Nutrition 0.000 description 22
- 235000001014 amino acid Nutrition 0.000 description 18
- 150000001413 amino acids Chemical class 0.000 description 13
- 230000002776 aggregation Effects 0.000 description 8
- 238000004220 aggregation Methods 0.000 description 8
- 125000003275 alpha amino acid group Chemical group 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 239000000178 monomer Substances 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 238000013459 approach Methods 0.000 description 6
- 238000005304 joining Methods 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 238000012856 packing Methods 0.000 description 5
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000002022 differential scanning fluorescence spectroscopy Methods 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 229940125644 antibody drug Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 238000011577 humanized mouse model Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000003000 inclusion body Anatomy 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000009437 off-target effect Effects 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 102220080600 rs797046116 Human genes 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 2
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 101100228196 Caenorhabditis elegans gly-4 gene Proteins 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 101001057612 Homo sapiens Dual specificity protein phosphatase 5 Proteins 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 241001436793 Meru Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 229940124691 antibody therapeutics Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000001378 electrochemiluminescence detection Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 102000043381 human DUSP5 Human genes 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000002818 protein evolution Methods 0.000 description 1
- 230000030788 protein refolding Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 239000011537 solubilization buffer Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1068—Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13003264 | 2013-06-26 | ||
| PCT/EP2014/001730 WO2014206561A1 (en) | 2013-06-26 | 2014-06-26 | Novel antibody frameworks |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL243311A0 IL243311A0 (en) | 2016-03-31 |
| IL243311B true IL243311B (en) | 2022-07-01 |
Family
ID=48699516
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL243311A IL243311B (en) | 2013-06-26 | 2014-06-26 | Novel antibody frameworks |
| IL313351A IL313351A (en) | 2013-06-26 | 2014-06-26 | New frameworks for antibodies |
| IL293477A IL293477B2 (en) | 2013-06-26 | 2014-06-26 | New frameworks for antibodies |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL313351A IL313351A (en) | 2013-06-26 | 2014-06-26 | New frameworks for antibodies |
| IL293477A IL293477B2 (en) | 2013-06-26 | 2014-06-26 | New frameworks for antibodies |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10174102B2 (OSRAM) |
| EP (1) | EP3013864A1 (OSRAM) |
| JP (4) | JP6708544B2 (OSRAM) |
| KR (4) | KR102286053B1 (OSRAM) |
| CN (2) | CN105579472B (OSRAM) |
| AU (2) | AU2014301629B2 (OSRAM) |
| CA (1) | CA2914829A1 (OSRAM) |
| HK (1) | HK1218549A1 (OSRAM) |
| IL (3) | IL243311B (OSRAM) |
| NZ (1) | NZ714320A (OSRAM) |
| SG (2) | SG11201509899PA (OSRAM) |
| WO (1) | WO2014206561A1 (OSRAM) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014206561A1 (en) | 2013-06-26 | 2014-12-31 | Numab Ag | Novel antibody frameworks |
| KR20180012860A (ko) | 2015-06-15 | 2018-02-06 | 누맙 이노베이션 아게 | 이종 이량체 다중 특이적 항체 포맷 |
| JP7080819B2 (ja) | 2016-02-25 | 2022-06-06 | セル メディカ スイッツァランド アーゲー | Ｐｄ－ｌ１に対する結合メンバー |
| IL261261B2 (en) | 2016-03-17 | 2024-04-01 | Numab Therapeutics AG | Antibodies against TNF-ALPHA and their functional fragments |
| HUE052773T2 (hu) | 2016-03-17 | 2021-05-28 | Tillotts Pharma Ag | Anti-TNF alfa antitestek és funkcionális fragmenseik |
| LT3219727T (lt) | 2016-03-17 | 2021-02-10 | Tillotts Pharma Ag | Anti-tnf alfa antikūnai ir jų funkciniai fragmentai |
| CN109071649B (zh) | 2016-03-17 | 2021-10-01 | 努玛创新有限公司 | 抗TNFα抗体及其功能片段 |
| SG11201808041UA (en) | 2016-03-17 | 2018-10-30 | Numab Innovation Ag | ANTI-TNFa-ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF |
| GB201621591D0 (en) * | 2016-12-19 | 2017-02-01 | Ucb Biopharma Sprl | Antibody molecules and method |
| ES3015094T3 (en) * | 2017-06-05 | 2025-04-29 | Numab Therapeutics AG | Anti-hsa antibodies |
| WO2018224441A1 (en) | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Novel anti-cd3 antibodies |
| MA49255A (fr) | 2017-06-05 | 2020-04-15 | Numab Therapeutics AG | Format d'anticorps hétérodimère multispécifique ciblant au moins cd3 et hsa |
| WO2018224439A1 (en) | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Novel anti-hsa antibodies |
| JP7247110B2 (ja) | 2017-06-05 | 2023-03-28 | ヌマブ セラピューティクス アクチェンゲゼルシャフト | 新規抗ｃｄ３抗体 |
| CN116948035A (zh) * | 2017-06-25 | 2023-10-27 | 西雅图免疫公司 | 多特异性抗体及其制备和使用方法 |
| US20200157224A1 (en) * | 2017-06-25 | 2020-05-21 | Systimmune, Inc. | Multi-specific antibodies and methods of making and using thereof |
| EP3459968A1 (en) * | 2017-09-20 | 2019-03-27 | Numab Innovation AG | Novel stable antibody variable domain framework combinations |
| EP3689907A1 (en) | 2019-01-31 | 2020-08-05 | Numab Therapeutics AG | Antibodies targeting il-17a and methods of use thereof |
| IL320091A (en) | 2019-01-31 | 2025-06-01 | Numab Therapeutics AG | Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof |
| JP2024501884A (ja) * | 2020-12-30 | 2024-01-16 | アセンド バイオテクノロジー インク | ヒトｍａｃ－１に対するモノクローナル抗体及びその使用 |
| CA3208905A1 (en) | 2021-02-12 | 2022-08-18 | Boehringer Ingelheim International Gmbh | Complement c3 antigen binding proteins |
| EP4305190A4 (en) | 2021-03-11 | 2025-03-26 | Iggenix, Inc. | METHODS AND SYSTEMS FOR PREDICTING AN ALLERGIC REACTION |
| US12344663B2 (en) | 2021-12-22 | 2025-07-01 | Cdr-Life Ag | Anti-C3 antibodies and antigen-binding fragments thereof and their uses for treating eye or ocular diseases |
| CN120882418A (zh) * | 2022-11-04 | 2025-10-31 | MiNK治疗公司 | B细胞成熟抗原(bcma)嵌合抗原受体不变自然杀伤t细胞及其用途 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009155723A2 (en) * | 2008-06-25 | 2009-12-30 | Esbatech, An Alcon Biomedical Research Unit Llc | STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα |
| WO2009155724A2 (en) * | 2008-06-25 | 2009-12-30 | Esbatech, An Alcon Biomedical Research Unit Llc | Stable and soluble antibodies inhibiting vegf |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE19819846B4 (de) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
| CN100415765C (zh) | 2003-08-07 | 2008-09-03 | 宜康公司 | 兔单克隆抗体的人源化方法 |
| WO2008004834A1 (en) | 2006-07-06 | 2008-01-10 | Isu Abxis Co., Ltd | Humanized monoclonal antibody highly binding to epidermal growth factor receptor, egf receptor |
| FR2910896B1 (fr) * | 2006-12-29 | 2012-11-16 | Lab Francais Du Fractionnement | Anticorps monoclonal dirige contre le recepteur humain des ldl |
| JP5859202B2 (ja) | 2007-05-21 | 2016-02-10 | アルダーバイオ・ホールディングズ・エルエルシー | 新規のウサギ抗体ヒト化方法及びヒト化ウサギ抗体 |
| PL2158315T3 (pl) | 2007-06-25 | 2016-10-31 | Sposoby modyfikowania przeciwciał i zmodyfikowane przeciwciała o ulepszonych właściwościach funkcjonalnych | |
| CN102164958A (zh) * | 2008-06-25 | 2011-08-24 | 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 | 使用通用抗体构架进行的兔抗体的人源化 |
| WO2010144780A1 (en) | 2009-06-12 | 2010-12-16 | University Of Kansas | Compositions and methods for establishing and maintaining stem cells in an undifferentiated state |
| EA201291133A1 (ru) * | 2010-04-30 | 2013-04-30 | Алексион Фармасьютикалз, Инк. | Антитела, обладающие пониженной иммуногенностью в организме человека |
| EP2726504A1 (en) * | 2011-05-27 | 2014-05-07 | Dutalys | Antibodies with improved folding stability |
| WO2014206561A1 (en) | 2013-06-26 | 2014-12-31 | Numab Ag | Novel antibody frameworks |
| EP3459968A1 (en) * | 2017-09-20 | 2019-03-27 | Numab Innovation AG | Novel stable antibody variable domain framework combinations |
-
2014
- 2014-06-26 WO PCT/EP2014/001730 patent/WO2014206561A1/en not_active Ceased
- 2014-06-26 IL IL243311A patent/IL243311B/en unknown
- 2014-06-26 JP JP2016522319A patent/JP6708544B2/ja active Active
- 2014-06-26 IL IL313351A patent/IL313351A/en unknown
- 2014-06-26 SG SG11201509899PA patent/SG11201509899PA/en unknown
- 2014-06-26 CN CN201480036689.1A patent/CN105579472B/zh active Active
- 2014-06-26 KR KR1020167001339A patent/KR102286053B1/ko active Active
- 2014-06-26 AU AU2014301629A patent/AU2014301629B2/en active Active
- 2014-06-26 NZ NZ714320A patent/NZ714320A/en unknown
- 2014-06-26 EP EP14737144.7A patent/EP3013864A1/en active Pending
- 2014-06-26 IL IL293477A patent/IL293477B2/en unknown
- 2014-06-26 SG SG10201811017QA patent/SG10201811017QA/en unknown
- 2014-06-26 KR KR1020227006072A patent/KR20220029763A/ko not_active Ceased
- 2014-06-26 CA CA2914829A patent/CA2914829A1/en active Pending
- 2014-06-26 CN CN202111136784.7A patent/CN113943366B/zh active Active
- 2014-06-26 KR KR1020217024096A patent/KR20210097829A/ko not_active Ceased
- 2014-06-26 US US14/900,550 patent/US10174102B2/en active Active
- 2014-06-26 KR KR1020237043185A patent/KR20240000622A/ko active Pending
- 2014-06-26 HK HK16106054.2A patent/HK1218549A1/zh unknown
-
2018
- 2018-10-10 US US16/156,036 patent/US11427628B2/en active Active
-
2019
- 2019-06-17 JP JP2019111990A patent/JP2019201643A/ja not_active Withdrawn
-
2020
- 2020-04-27 AU AU2020202770A patent/AU2020202770B2/en active Active
-
2021
- 2021-10-14 JP JP2021169020A patent/JP2022028659A/ja active Pending
-
2022
- 2022-08-29 US US17/822,959 patent/US20230212265A1/en active Pending
-
2023
- 2023-11-27 JP JP2023199881A patent/JP2024026176A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009155723A2 (en) * | 2008-06-25 | 2009-12-30 | Esbatech, An Alcon Biomedical Research Unit Llc | STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα |
| WO2009155724A2 (en) * | 2008-06-25 | 2009-12-30 | Esbatech, An Alcon Biomedical Research Unit Llc | Stable and soluble antibodies inhibiting vegf |
Non-Patent Citations (1)
| Title |
|---|
| EWERT, STEFAN; HONEGGER, ANNEMARIE; PL?CKTHUN, ANDREAS, STABILITY IMPROVEMENT, 1 October 2004 (2004-10-01) * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230212265A1 (en) | Novel antibody frameworks | |
| JP2016523537A5 (OSRAM) | ||
| CA3073882A1 (en) | Novel stable antibody variable domain framework combinations | |
| CA2853383A1 (en) | Bispecific antibodies comprising two paratopes in one complementary vh-vl pair | |
| IL271127B1 (en) | New anti-HSA antibodies | |
| IL271128B1 (en) | New anti-3CD antibodies | |
| IL270308B1 (en) | Anti-interferon gamma antibodies and uses thereof | |
| WO2018224439A1 (en) | Novel anti-hsa antibodies | |
| IL256263A (en) | Cys80-linked immunoglobulins | |
| IL298076A (en) | Multispecific antibodies | |
| HK40023336A (en) | Anti-hsa antibodies | |
| HK40023336B (en) | Anti-hsa antibodies |